How does the recent FDA approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) change how you image and manage patients with metastatic castrate-resistant prostate cancer?  

When do you order PSMA PET and will you preferably order Locametz (gallium Ga 68 gozetotide) PET?